Novo Nordisk partners with Anthropic to accelerate drug discovery

Novo Nordisk has entered into a $1.4bn drug deal partnership with Orbis Medicines. Additionally, Novo Nordisk is collaborating with Anthropic to accelerate drug discovery processes. This AI partnership aims to revolutionize drug development by potentially reducing overall costs and timelines. These strategic moves are expected to intensify competition within the pharmaceutical industry as Novo Nordisk leverages advanced technology and significant financial investments to enhance its research and development capabilities for new medical treatments.